Novo Nordisk targets obesity

Novo Nordisk A/S, a global producer of diabetes products, reported little change in its sales and a 1% increase in operating profit in 2017 at respectively DKK 112 billion (€15.05 billion) and DKK 49 billion.

Full text available to subscribers only. Click here for information on subscribing to MedNous.